vs
Comstock Holding Companies, Inc.（CHCI）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
RECURSION PHARMACEUTICALS, INC.的季度营收约是Comstock Holding Companies, Inc.的1.5倍（$35.5M vs $23.9M），Comstock Holding Companies, Inc.净利率更高（56.3% vs -304.2%，领先360.5%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 41.5%），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 50.0%）
该条目原介绍康斯托克矿脉的地理与发现背景，并非企业经营信息，康斯托克控股公司是一家美国企业，相关公开经营业务信息暂缺。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
CHCI vs RXRX — 直观对比
营收规模更大
RXRX
是对方的1.5倍
$23.9M
营收增速更快
RXRX
高出640.2%
41.5%
净利率更高
CHCI
高出360.5%
-304.2%
两年增速更快
RXRX
近两年复合增速
50.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $23.9M | $35.5M |
| 净利润 | $13.5M | $-108.1M |
| 毛利率 | 35.5% | 59.8% |
| 营业利润率 | 32.4% | -304.8% |
| 净利率 | 56.3% | -304.2% |
| 营收同比 | 41.5% | 681.7% |
| 净利润同比 | 30.5% | 39.6% |
| 每股收益（稀释后） | — | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CHCIRXRX
| Q4 25 | $23.9M | $35.5M | ||
| Q3 25 | $13.3M | $5.2M | ||
| Q2 25 | $13.0M | $19.2M | ||
| Q1 25 | $12.6M | $14.7M | ||
| Q4 24 | $16.9M | $4.5M | ||
| Q3 24 | $13.0M | $26.1M | ||
| Q2 24 | $10.8M | $14.4M | ||
| Q1 24 | $10.6M | $13.8M |
净利润CHCIRXRX
| Q4 25 | $13.5M | $-108.1M | ||
| Q3 25 | $541.0K | $-162.3M | ||
| Q2 25 | $1.4M | $-171.9M | ||
| Q1 25 | $1.6M | $-202.5M | ||
| Q4 24 | $10.3M | $-178.9M | ||
| Q3 24 | $2.4M | $-95.8M | ||
| Q2 24 | $946.0K | $-97.5M | ||
| Q1 24 | $910.0K | $-91.4M |
毛利率CHCIRXRX
| Q4 25 | 35.5% | 59.8% | ||
| Q3 25 | 11.0% | -183.8% | ||
| Q2 25 | 19.0% | -4.9% | ||
| Q1 25 | 18.6% | -48.0% | ||
| Q4 24 | 33.4% | -181.4% | ||
| Q3 24 | 26.3% | 53.7% | ||
| Q2 24 | 17.2% | 36.2% | ||
| Q1 24 | 16.5% | 19.1% |
营业利润率CHCIRXRX
| Q4 25 | 32.4% | -304.8% | ||
| Q3 25 | 5.0% | -3327.6% | ||
| Q2 25 | 13.7% | -916.8% | ||
| Q1 25 | 13.7% | -1297.9% | ||
| Q4 24 | 30.1% | -4042.4% | ||
| Q3 24 | 21.8% | -377.1% | ||
| Q2 24 | 11.4% | -697.4% | ||
| Q1 24 | 10.8% | -698.4% |
净利率CHCIRXRX
| Q4 25 | 56.3% | -304.2% | ||
| Q3 25 | 4.1% | -3135.3% | ||
| Q2 25 | 11.1% | -894.2% | ||
| Q1 25 | 12.6% | -1373.3% | ||
| Q4 24 | 61.1% | -3935.5% | ||
| Q3 24 | 18.3% | -367.5% | ||
| Q2 24 | 8.8% | -676.6% | ||
| Q1 24 | 8.6% | -662.4% |
每股收益（稀释后）CHCIRXRX
| Q4 25 | — | $-0.17 | ||
| Q3 25 | — | $-0.36 | ||
| Q2 25 | — | $-0.41 | ||
| Q1 25 | — | $-0.50 | ||
| Q4 24 | — | $-0.56 | ||
| Q3 24 | — | $-0.34 | ||
| Q2 24 | — | $-0.40 | ||
| Q1 24 | $0.09 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $31.3M | $743.3M |
| 总债务越低越好 | — | $9.6M |
| 股东权益账面价值 | $70.0M | $1.1B |
| 总资产 | $85.0M | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资CHCIRXRX
| Q4 25 | $31.3M | $743.3M | ||
| Q3 25 | $26.2M | $659.8M | ||
| Q2 25 | $30.5M | $525.1M | ||
| Q1 25 | $28.3M | $500.5M | ||
| Q4 24 | $28.8M | $594.4M | ||
| Q3 24 | $21.1M | $427.6M | ||
| Q2 24 | $17.4M | $474.3M | ||
| Q1 24 | $16.2M | $296.3M |
总债务CHCIRXRX
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | — |
股东权益CHCIRXRX
| Q4 25 | $70.0M | $1.1B | ||
| Q3 25 | $56.3M | $1.0B | ||
| Q2 25 | $55.5M | $919.1M | ||
| Q1 25 | $53.7M | $933.9M | ||
| Q4 24 | $52.4M | $1.0B | ||
| Q3 24 | $41.7M | $524.6M | ||
| Q2 24 | $39.2M | $584.4M | ||
| Q1 24 | $37.9M | $401.2M |
总资产CHCIRXRX
| Q4 25 | $85.0M | $1.5B | ||
| Q3 25 | $67.6M | $1.4B | ||
| Q2 25 | $65.2M | $1.3B | ||
| Q1 25 | $62.8M | $1.3B | ||
| Q4 24 | $64.9M | $1.4B | ||
| Q3 24 | $52.2M | $726.5M | ||
| Q2 24 | $48.6M | $775.9M | ||
| Q1 24 | $46.8M | $557.8M |
负债/权益比CHCIRXRX
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.8M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | — | $-47.3M |
| 自由现金流率自由现金流/营收 | — | -133.1% |
| 资本支出强度资本支出/营收 | — | 3.5% |
| 现金转化率经营现金流/净利润 | 0.36× | — |
| 过去12个月自由现金流最近4个季度 | — | $-378.3M |
8季度趋势，按日历期对齐
经营现金流CHCIRXRX
| Q4 25 | $4.8M | $-46.1M | ||
| Q3 25 | $-3.2M | $-117.4M | ||
| Q2 25 | $2.2M | $-76.4M | ||
| Q1 25 | $582.0K | $-132.0M | ||
| Q4 24 | $10.7M | $-115.4M | ||
| Q3 24 | $3.9M | $-59.2M | ||
| Q2 24 | $1.3M | $-82.2M | ||
| Q1 24 | $-2.2M | $-102.3M |
自由现金流CHCIRXRX
| Q4 25 | — | $-47.3M | ||
| Q3 25 | — | $-117.6M | ||
| Q2 25 | — | $-79.6M | ||
| Q1 25 | — | $-133.8M | ||
| Q4 24 | — | $-116.7M | ||
| Q3 24 | — | $-63.8M | ||
| Q2 24 | — | $-83.4M | ||
| Q1 24 | — | $-109.0M |
自由现金流率CHCIRXRX
| Q4 25 | — | -133.1% | ||
| Q3 25 | — | -2272.5% | ||
| Q2 25 | — | -413.9% | ||
| Q1 25 | — | -907.4% | ||
| Q4 24 | — | -2567.7% | ||
| Q3 24 | — | -244.6% | ||
| Q2 24 | — | -578.5% | ||
| Q1 24 | — | -789.9% |
资本支出强度CHCIRXRX
| Q4 25 | — | 3.5% | ||
| Q3 25 | — | 4.7% | ||
| Q2 25 | — | 16.4% | ||
| Q1 25 | — | 12.4% | ||
| Q4 24 | — | 28.6% | ||
| Q3 24 | — | 17.5% | ||
| Q2 24 | — | 8.2% | ||
| Q1 24 | — | 48.2% |
现金转化率CHCIRXRX
| Q4 25 | 0.36× | — | ||
| Q3 25 | -5.96× | — | ||
| Q2 25 | 1.51× | — | ||
| Q1 25 | 0.37× | — | ||
| Q4 24 | 1.03× | — | ||
| Q3 24 | 1.63× | — | ||
| Q2 24 | 1.35× | — | ||
| Q1 24 | -2.46× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CHCI
| Related Party | $22.1M | 92% |
| Nonrelated Party | $1.9M | 8% |
RXRX
暂无分部数据
